Immunoglobulin News and Research

RSS

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

A team of international scientists has recently developed a bispecific antibody that can bind two non-overlapping regions of the spike receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and completely prevent the viral-host interaction.

25 Jan 2021

Infusion of convalescent blood plasma benefits patient with severe COVID-19

A 72-year-old woman was hospitalized with severe COVID-19 disease, 33 days after the onset of symptoms.

22 Jan 2021

Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant

Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

21 Jan 2021

SARS-CoV-2 suppresses host innate immunity

SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.

21 Jan 2021

South African SARS-CoV-2 variant escapes antibody neutralization

Researchers in South Africa have conducted a study showing that the novel 501Y.V2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in the country is able to escape the neutralizing antibodies that are elicited by previously circulating strains of the virus.

20 Jan 2021

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

In an exciting, state-of-the-art study currently available on the medRxiv* preprint server, US researchers created a multi-coronavirus protein microarray containing full-length proteins, peptide libraries, and overlapping protein fragments from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as four other human coronaviruses.

19 Jan 2021

Memory B cell response to SARS-CoV-2 evolves up to 6 months after infection, study finds

A new study shows that the memory B cell response to SARS-Cov-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.

19 Jan 2021

Study predicts good passive immunotherapy donors to combat COVID-19

A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.

19 Jan 2021

Study sheds light on the causes of debilitating gut pain

A new study, published in the journal Nature, reports evidence from mice and humans that a novel mechanism contributes to chronic gut pain.

17 Jan 2021

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

Study shows why antihistamine drugs fail to control severe itch in eczema patients

In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that itching can become torturous. Worse, antihistamines -- the standard treatment for itching and allergy -- often don't help.

15 Jan 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.

12 Jan 2021

Sustained immune response memory detected in recovered COVID-19 patients

A team of researchers at the University of Washington School of Medicine has found that people who had mild COVID-19 developed a multi-layered immune response against SARS-Cov-2. The researchers detected neutralizing antibodies against the virus for at least three months after recovering from the infection.

11 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

As the world struggles to contain the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for over 1.6 million deaths and 76 million infections globally, researchers are trying to pin down the determinants of lethality, of infectivity and of protection. Such data would help contain its spread and develop preventive and therapeutic antivirals and vaccines. A new preprint that appeared recently on the bioRxiv* server describes the high degree of protection afforded by antibodies that target the N-terminal domain (NTD) of the virus.

24 Dec 2020

Higher BMI linked to increased risk of SARS-CoV-2 infection

Researchers at the University of Miami Miller School of Medicine, USA, revealed that the spike-specific immunoglobulin G antibodies in obese people are negatively associated with body mass index (BMI) and serum levels of proinflammatory and metabolic markers of pulmonary inflammation.

24 Dec 2020

Abbott gets CE Mark for new quantitative SARS-CoV-2 IgG lab-based serology test

Abbott announced today it received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test.

18 Dec 2020

Immunoglobulin News and Research

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

Infusion of convalescent blood plasma benefits patient with severe COVID-19

Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant

SARS-CoV-2 suppresses host innate immunity

South African SARS-CoV-2 variant escapes antibody neutralization

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

Memory B cell response to SARS-CoV-2 evolves up to 6 months after infection, study finds

Study predicts good passive immunotherapy donors to combat COVID-19

Study sheds light on the causes of debilitating gut pain

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

Study shows why antihistamine drugs fail to control severe itch in eczema patients

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

Sustained immune response memory detected in recovered COVID-19 patients

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

Higher BMI linked to increased risk of SARS-CoV-2 infection

Abbott gets CE Mark for new quantitative SARS-CoV-2 IgG lab-based serology test

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News